Skip to main content

Table 3 Calendar periods and distributions of lymphoma diagnoses, selected characteristics, and mortality

From: The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016

Category

1994–1999

2000–2009

2010–2016

Total

N

%

N

%

N

%

N

%

Aggressive B-cell lymphoma

10

23.8

46

28.6

49

21.3

105

24.3

Indolent lymphoma

14

33.3

47

29.2

46

20.0

107

24.7

Of which transformed

4

28.6

31

66.0

35

76.1

70

65.4

Mantle cell lymphoma

2

4.8

27

16.8

55

23.9

84

19.4

T-cell lymphoma

6

14.3

23

14.3

37

16.1

66

15.2

Hodgkin lymphoma

10

23.8

18

11.2

23

10.0

51

11.8

Primary CNS lymphoma

0

0

0

0

20

8.7

20

4.6

Harvest < 5 million CD34 +/kg

22

64.7

36

23.2

51

22.2

109

26.0

Upfront transplantation

3

7.1

46

28.6

106

46.1

155

35.8

Age > 65 years

0

0

19

11.8

66

28.7

85

19.6

100-day overall mortality

4

9.5

14

8.7

13

5.7

31

7.2

100-day non-relapse mortality

4

9.5

11

7.0

9

4.0

24

5.6

100-day lymphoma mortality

0

0

3

2.0

4

1.8

7

1.7

6-month overall mortalitya

 

14.3

 

13.1

 

7.4

 

10.2

6-month non-relapse mortalitya

 

11.9

 

6.0

 

3.9

 

6.3

6-month lymphoma mortalitya

 

2.7

 

5.3

 

3.6

 

4.2

1-year overall mortalitya

 

28.6

 

19.9

 

16.6

 

19.0

1-year non-relapse mortalitya

 

17.1

 

6.8

 

4.4

 

7.6

1-year lymphoma mortalitya

 

13.8

 

11.5

 

12.8

 

12.4

  1. aThese values are estimated using survival analysis, why only percentages can be extracted